Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma
Table 1
Patient and tumour characteristics and survival estimate rates (95% CI) at 36 months after diagnosis.
Patients (%) (total = 149)
Cumulative survival 36 months (%)
Median
value
HR
95% CI
Sex
Men
85 (57%)
24
22
0.72
1
Women
64 (43%)
24
20
1.07
0.73–1.56
Age (years)
<50
17 (11.4%)
41
27
0.14
1
50–69
80 (53.7%)
26
23
1.76
0.88–3.52
>70
52 (34.9%)
16
16
1.29
0.66–2.54
Location
Right colon
64 (43%)
15
17
0.21
1
Left colon
64 (43%)
32
25
0.86
0.49–1.51
Rectum
21 (14%)
19
24
0.69
0.46–1.05
ECOG Index
0
34 (22.8%)
47
36
<0.001
1
1.47–4.19
1-2
115 (77.2%)
17
17
2.49
T stage
T3
68 (45.6%)
26
24
0.42
1
T4
81 (54.6%)
23
19
1.16
0.79–1.7
N stage
N0
27 (18%)
51
NR
<0.001
1
1.55–5.19
N1-2
122 (81%)
18
21
2.84
Time of diagnostics
Synchronic
77 (51.7%)
14
18
0.03
1
Metachronic
72 (48.3%)
26
26
0.65
0.44–0.96
Site of metastases
Peritoneum only
61 (40.9%)
33
25
0.01
1
Peritoneum + liver
51 (34.2%)
27
21
2.08
1.26–3.41
Peritoneum + lung
8 (5.4%)
12
15
2
0.89–4.5
Multiple
29 (19.5%)
6
13
1.27
0.8–2.01
Grade of differentiation
Well to moderate
111 (74.5%)
30
25
<0.001
1
Poor
38 (25.5%)
6
12
2.36
1.56–3.57
Histologic type
Classical adenocarcinoma
105 (70.5%)
31
27
<0.001
1
Mucinous
44 (29.5%)
9
12
2.54
1.7–3.8
KRAS status
WT-KRAS
74 (49.7%)
35
28
<0.001
1
1.48–3.2
MT-KRAS
75 (50.3%)
14
15
2.18
Peritoneal cancer index
1–10
46 (30.9%)
56
NR
<0.001
1
11–20 (a)
63 (42.3%)
10
22
7.43
4.16–13.24
>20 (b)
40 (28.8%)
0
13
2.59
1.53–4.36
Chemotherapy treatment
5-FU-based programs plus bevacizumab/cetuximab
103 (69.1%)
52
NR
<0.001
1
5-FU-based programs
46 (30.9%)
9
14
2.86
1.92–4.24
Primary tumour resection
Yes
130 (87.2%)
27
22
<0.001
1
No
19 (12.8%)
0
15
2.29
1.34–3.90
HIPEC
Yes
36 (75.8%)
64
60
<0.001
1
No
113 (24.2%)
11
15
5.45
2.98–10.04
The log-rank test was used to calculate values. HR: hazard ratio; 95% CI: 95% confidence interval; NR: not reached. Hazard ratio compares PCI: (a) PCI 11–20 versus PCI 1–10; (b) PCI >20 versus PCI 11–20.